Scholarlink

Purpose of Review <p>This review evaluates current evidence on tapering strategies for anti–type 2 biologics in chronic inflammatory diseases. Given the need for long-term treatment, optimizing dosage without compromising efficacy is essential for sustainable disease management.</p> Recent Findings <p>Biologic dose reduction strategies, such as tapering, de-escalation, dose spacing and interval dose prolongation, are increasingly explored in various type 2 inflammatory diseases, particularly in real-life settings. Studies have shown variable outcomes depending on disease type, patient characteristics, and tapering methods.</p> Summary <p>Nineteen studies met inclusion criteria in this systematic review. The evidence supports the feasibility of dose tapering, especially for dupilumab, in maintaining disease control while reducing drug exposure. However, standardized tapering protocols and clear patient selection criteria remain lacking. Further prospective, controlled studies are needed to define optimal, safe, and personalized de-escalation strategies for long-term management of type 2 inflammatory diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Strategies for Tapering the Dosage of Biologics Targeting Type 2 Inflammation: A Systematic Review

  • 期刊论文

  • 发表日期：

    2025年7月28日

查看全文
  • Antonella Loperfido,
  • Claudio Montuori,
  • Marco Caminati,
  • Niccolò Gori,
  • Leandro Maria D’Auria,
  • Gianluca Bellocchi,
  • Carlo Cavaliere,
  • Daniela Lucidi,
  • Moffa Antonio,
  • Eugenio De Corso

摘要

Purpose of Review

This review evaluates current evidence on tapering strategies for anti–type 2 biologics in chronic inflammatory diseases. Given the need for long-term treatment, optimizing dosage without compromising efficacy is essential for sustainable disease management.

Recent Findings

Biologic dose reduction strategies, such as tapering, de-escalation, dose spacing and interval dose prolongation, are increasingly explored in various type 2 inflammatory diseases, particularly in real-life settings. Studies have shown variable outcomes depending on disease type, patient characteristics, and tapering methods.

Summary

Nineteen studies met inclusion criteria in this systematic review. The evidence supports the feasibility of dose tapering, especially for dupilumab, in maintaining disease control while reducing drug exposure. However, standardized tapering protocols and clear patient selection criteria remain lacking. Further prospective, controlled studies are needed to define optimal, safe, and personalized de-escalation strategies for long-term management of type 2 inflammatory diseases.